Table 1.

Origin and properties of the S. aureus strains

StrainDate of isolation (mo/yr)OriginPatient’s therapyResistance phenotypeaRifampin MIC (μg/ml)
BM46264/1992BoneRifampin plus pefloxacinTc0.008
BM46274/1992Pef Rif Tc128–256
BM43642/1996BoneVancomycin, followed by rifampin plus pristinamycinEmc Fos Fus Km Met Pc Pef Tm0.008
BM4364-R3/1996Emc Fos Fus Km Met Pc Pef Rif Tm256
BM43656/1996BloodRifampinPc0.008
BM4365-R10/1996Pc Rif256
BM43661/1997SkinRifampinPc Emc 0.008
BM4366-R1/1997Pc EmcRif128–256
BM43673/1997UrineRifampin plus vancomycinEmc Fos Km Met Pc Pef Tm0.016
BM4367-R4/1997Urine and pulmonary treeEmc Fos Km Met Pc Pef Rif Tm4
BM43683/1997UrineRifampin plus vancomycinPc Tc0.016
BM4368-R1 3/1997Pulmonary treeRifampin plus vancomycinPc Rif Tc128
BM4368-R2 4/1997Pulmonary treePc Rif Tc4
  • a Emc, constitutive resistance to macrolide, lincosamide, and streptogramin β-type antibiotics; Fos, resistance to fosfomycin; Fus, resistance to fusidic acid; Km, resistance to kanamycin; Met, resistance to methicillin; Pc, resistance to penicillin G; Pef, resistance to pefloxacin; Rif, resistance to rifampin; Tm, resistance to tobramycin.